TNF and cancer: In patients exposed to anti-TNFα agents we observed a non-significantly decreased risk for developing a malignancy compared to patients treated with conventional DMARDs (adjusted HR = 0.70; 95% CI: 0.44 to 1.12, P = 0.13).